• Explore /
  • Poster
  • / Clinical pharmacokinetics of bdtx-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies in MasterKey-01 study.

Clinical pharmacokinetics of bdtx-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies in MasterKey-01 study.

Abstract Video & Slides Poster

Authors

null

Nigel Waters

Black Diamond Therapeutics, Inc, Cambridge, MA

Nigel Waters , Manish R. Patel , Alison M. Schram , Jordi Rodon Ahnert , Shekeab Jauhari , Jasgit C. Sachdev , Viola Weijia Zhu , Patricia LoRusso , Danny Nguyen , David S. Hong , Leticia Tarilonte , Rachel W. Humphrey , Pasi A. Janne , Erika P. Hamilton , Karsten Witt

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Pharmacology/Pharmacodynamics/Pharmacogenetics

Clinical Trial Registration Number

NCT04209465

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 3097)

DOI

10.1200/JCO.2021.39.15_suppl.3097

Abstract #

3097

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Alison M. Schram

First Author: Erika Paige Hamilton

First Author: M. Simonelli

First Author: Heejung Chae